April 22, 2024
Introduction to NINLARO® (ixazomib) in combination with lenalidomide NINLARO® (ixazomib) in combination with lenalidomide is a treatment strategy used for multiple myeloma, a type of cancer […]
April 20, 2024
Understanding Diffuse Lower-Grade Glioma is crucial for providing effective strategies to enhance the quality of life for patients.
Diffuse lower-grade gliomas are brain tumors that have distinct characteristics and challenges.
April 12, 2024
Mercaptopurine, often referred to by its chemical name 6-mercaptopurine or simply 6-MP, stands as a pivotal medication in the oncology sphere, particularly within the context of treating childhood Acute Lymphoblastic Leukemia (ALL).
March 25, 2024
Rabies is a viral disease that is primarily transmitted through the bite or scratch of an infected animal. The rabies virus is typically found in the saliva of infected animals and can be transmitted to humans through contact with the saliva, usually via a bite.
February 27, 2024
Learn how addressing social determinants of health can promote health equity and improve public health outcomes. Explore initiatives within Medicaid and other sectors.
February 27, 2024
Discover the symptoms, causes, and treatments of sleep apnea. Learn how this common disorder causes breathing disruptions during sleep and how to manage it.
February 26, 2024
The ingredients listed in the PANTOVIGAR vegan capsules are generally considered safe and are not known to have a significant impact on kidney function or renal failure patients. However, it’s important to note that individual responses to supplements can vary, especially in the context of renal failure.
February 26, 2024
Mannitol is used after cisplatin treatment to prevent or reduce the risk of cisplatin-induced nephrotoxicity, which is a major concern associated with cisplatin chemotherapy. Cisplatin is a widely used chemotherapeutic drug for various types of cancer, but its use is often limited by its potential to cause kidney damage.
February 24, 2024
Heparin, available as both unfractionated and low-molecular-weight forms, has been extensively studied for its potential benefits in cancer patients. Low molecular weight heparin's role in both preventing and treating venous thromboembolism in patients, a common complication in cancer patients, has been the subject of systematic review and numerous randomized clinical trials. Furthermore, heparin has shown promising effects in managing VTE in patients undergoing cancer therapy, including those with advanced pancreatic cancer.
